


PRODUCT INFORMATION



Lometrexol (hydrate)

Item No. 18049

Formal Name: N-[4-[2-[(6R)-2-amino-3,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]-L-glutamic acid, hydrate
Synonyms: DDATHF, (6R)-Dideazatetrahydrofolate
MF: C₂₁H₂₅N₅O₆ • XH₂O
FW: 443.5
Purity: ≥98%
UV/Vis.: λ_{max}: 224, 279 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Lometrexol (hydrate) is supplied as a crystalline solid. A stock solution may be made by dissolving the lometrexol (hydrate) in the solvent of choice, which should be purged with an inert gas. Lometrexol (hydrate) is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of lometrexol (hydrate) in these solvents is approximately 20 and 5 mg/ml, respectively.

Lometrexol (hydrate) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, lometrexol (hydrate) should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Lometrexol (hydrate) has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Glycinamide ribonucleotide formyltransferase (GART) is a folate-dependent enzyme required for *de novo* purine synthesis. Lometrexol is a folate analog antimetabolite with antineoplastic activity.^{1,2} At nanomolar concentrations, it inhibits GART preventing *de novo* purine synthesis, inhibiting DNA synthesis, arresting cells in the S phase of the cell cycle, and inhibiting tumor cell proliferation.³

References

1. Beardsley, G.P., Moroson, B.A., Taylor, E.C., *et al.* A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of *de novo* purine synthesis. *J. Biol. Chem.* **264**(1), 328-333 (1989).
2. Pizzorno, G., Moroson, B.A., Cashmore, A.R., *et al.* (6R)-5,10-Dideaza-5,6,7,8-tetrahydrofolic acid effects on nucleotide metabolism in CCRF-CEM human T-lymphoblast leukemia cells. *Cancer Res.* **51**(9), 2291-2295 (1991).
3. Bronder, J.L. and Moran, R.G. Antifolates targeting purine synthesis allow entry of tumor cells into S phase regardless of p53 function. *Cancer Res.* **62**(18), 5236-5241 (2002).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/06/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM